Video

What Challenges Are Associated with Achieving Provider Status?

Conference|ASHP Pharmacy Futures Meeting and Exhibition - American Society of Health System Pharmacists Summer Meeting and Exhibition

In this clip, Christopher Topoleski, Director of Federal Legislative Affairs for ASHP, discusses the major challenges involved in achieving provider status for pharmacists.

In this clip, Christopher Topoleski, Director of Federal Legislative Affairs for ASHP, discusses the major challenges involved in achieving provider status for pharmacists.

Related Videos
Related Content
Pharmacist, customer or support in shop with medicine, shopping with professional help. Pharmacy, people or together for healthcare service with advice for dosage, pill information for woman with flu
March 31st 2025

Expert Q&A: Role of Pharmacists in COVID-19 Care, Prevention Continues to Evolve

Luke Halpern, Assistant Editor Corey Frederick, PharmD, BCPS, BCIDP, CPh
Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder
March 31st 2025

Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder

Luke Halpern, Assistant Editor
Exploring the Tumor Microenvironment Interactions Between Cancer Cells, TCells, and Nanoparticles in Cancer Therapy and Immunology
March 31st 2025

NCCN 2025: Managing Immune Checkpoint Inhibitor-Related Toxicities in Cancer Care

Luke Halpern, Assistant Editor
Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education
February 28th 2025

Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education

Luke Halpern, Assistant Editor Jill Simonian, PharmD Codi Peterson, PharmD, MS
ACC 2025: Intravenous Iron Safe, but Results in Mixed Findings for Patients With Heart Failure
March 30th 2025

ACC 2025: Intravenous Iron Safe, but Results in Mixed Findings for Patients With Heart Failure

Aislinn Antrim, Managing Editor
ACC 2025: Oral Semaglutide Reduces Cardiovascular Events by 14% at 4 Years
March 30th 2025

ACC 2025: Oral Semaglutide Reduces Cardiovascular Events by 14% at 4 Years

Aislinn Antrim, Managing Editor